Targeted radiation for certain receptor-positive tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older, and have advanced NETs (or specific related tumors) or meningioma confirmed by pathology.
- Your tumor must have measurable spots on a recent CT or MRI scan, and those spots must have been growing or worsening in the past year.
- Your tumor must be confirmed to have somatostatin receptor activity on a special PET scan (SSTR PET).
- You must be able to do daily activities fairly normally (ECOG performance status 0–1) and expect to live more than 3 months.
- You must not have had prior systemic PRRT radiation (like lutetium or yttrium DOTATATE/DOTATOC).
- You must be able to follow safety rules for radiation and, if you can get pregnant or cause pregnancy, use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This trial tests a new type of radiation therapy for advanced neuroendocrine cancers that have not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.
This trial studies whether it’s helpful to keep taking somatostatin “analog” injections even after your neuroendocrine tumor has started growing despite the usual dose. It also looks at how the next treatment choice (targeted pills or PRRT) fits in for people with non-functional, well-differentiated GEP NET.
This early-stage trial tests a new radioactive drug (called [212Pb]VMT-Alpha-NET) that targets a marker on certain cancer cells. It may help shrink or slow the growth of tumors that have spread or can't be removed, and it's being studied for several cancer types, including neuroendocrine tumors, small cell lung cancer, kidney cancer, and some head and neck cancers.
Hear when a new Gastroenteropancreatic Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.